# Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors

> **NCT04764084** · PHASE1 · UNKNOWN · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 52 (estimated)

## Conditions studied

- HER2-negative Breast Cancer
- Gastric Adenocarcinoma
- Cholangiocarcinoma
- Pancreatic Cancer

## Interventions

- **DRUG:** Niraparib
- **DRUG:** Anlotinib

## Key facts

- **NCT ID:** NCT04764084
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-01
- **Primary completion:** 2021-11-01
- **Final completion:** 2023-02-28
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2021-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04764084

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04764084, "Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04764084. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*